| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 02/05/2024 | 16:07 | InvestorsHub NewsWire | NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon | AMEX:NNVC | NanoViricides Inc |
| 16/02/2024 | 22:53 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NNVC | NanoViricides Inc |
| 14/02/2024 | 22:55 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | AMEX:NNVC | NanoViricides Inc |
| 04/12/2023 | 22:08 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | AMEX:NNVC | NanoViricides Inc |
| 13/10/2023 | 22:30 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | AMEX:NNVC | NanoViricides Inc |
| 28/09/2023 | 22:44 | Edgar (US Regulatory) | Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | AMEX:NNVC | NanoViricides Inc |
| 06/07/2023 | 17:16 | InvestorsHub NewsWire | Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs | AMEX:NNVC | NanoViricides Inc |
| 25/05/2023 | 22:34 | Edgar (US Regulatory) | Current Report Filing (8-k) | AMEX:NNVC | NanoViricides Inc |
| 08/05/2023 | 23:20 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) | AMEX:NNVC | NanoViricides Inc |
| 04/05/2023 | 12:45 | GlobeNewswire Inc. | NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City | AMEX:NNVC | NanoViricides Inc |
| 14/02/2023 | 23:24 | Edgar (US Regulatory) | Quarterly Report (10-q) | AMEX:NNVC | NanoViricides Inc |
| 23/12/2022 | 12:04 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | AMEX:NNVC | NanoViricides Inc |
| 15/11/2022 | 22:32 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | AMEX:NNVC | NanoViricides Inc |
| 04/11/2022 | 21:33 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | AMEX:NNVC | NanoViricides Inc |
| 13/10/2022 | 23:13 | Edgar (US Regulatory) | Annual Report (10-k) | AMEX:NNVC | NanoViricides Inc |
| 29/09/2022 | 18:20 | Edgar (US Regulatory) | Notification That Annual Report Will Be Submitted Late (nt 10-k) | AMEX:NNVC | NanoViricides Inc |
| 11/08/2022 | 00:52 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | AMEX:NNVC | NanoViricides Inc |
| 15/11/2021 | 13:09 | InvestorsHub NewsWire | NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2 | AMEX:NNVC | NanoViricides Inc |
| 11/10/2021 | 12:49 | InvestorsHub NewsWire | NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity | AMEX:NNVC | NanoViricides Inc |
| 05/10/2021 | 12:45 | PR Newswire (US) | NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference | AMEX:NNVC | NanoViricides Inc |
| 22/09/2021 | 12:48 | InvestorsHub NewsWire | Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug | AMEX:NNVC | NanoViricides Inc |
| 14/09/2021 | 13:02 | InvestorsHub NewsWire | NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development | AMEX:NNVC | NanoViricides Inc |
| 09/03/2021 | 15:30 | InvestorsHub NewsWire | NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in ....Cont | AMEX:NNVC | NanoViricides Inc |
| 02/03/2021 | 13:00 | InvestorsHub NewsWire | NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical | AMEX:NNVC | NanoViricides Inc |
| 17/02/2021 | 13:00 | InvestorsHub NewsWire | NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug ....cont | AMEX:NNVC | NanoViricides Inc |
| 16/02/2021 | 15:48 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | AMEX:NNVC | NanoViricides Inc |
| 08/02/2021 | 12:36 | InvestorsHub NewsWire | NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP..C... | AMEX:NNVC | NanoViricides Inc |
| 27/01/2021 | 13:00 | InvestorsHub NewsWire | Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants | AMEX:NNVC | NanoViricides Inc |
| 03/12/2020 | 22:31 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | AMEX:NNVC | NanoViricides Inc |
| 19/11/2020 | 12:47 | InvestorsHub NewsWire | NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA | AMEX:NNVC | NanoViricides Inc |